STOCK TITAN

Cv Sciences - CVSI STOCK NEWS

Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.

Overview

CV Sciences, Inc. is a comprehensive consumer wellness company that integrates science and nature to improve overall health and well-being. Specializing in nutraceuticals and plant-based foods, the company brings together scientifically-backed hemp extracts and natural ingredients across a diverse range of products. By leveraging deep research, clinical validations, and independent testing, CV Sciences positions itself as an informed and reliable entity in the health and wellness sector.

Core Business and Strategic Focus

The core mission of CV Sciences is to make healthy people healthier. The company’s operations span the development, manufacturing, and distribution of wellness products that cater to both human and pet consumers. Its business model is anchored on the production of hemp-based supplements and plant-derived food products that are sold through multiple channels including direct-to-consumer (B2C) and business-to-business (B2B) outlets. The product portfolio is carefully developed with an emphasis on science and quality, ensuring that each offering is supported by clinical research and complies with industry safety standards.

Product Portfolio and Innovation

CV Sciences offers an expansive range of product lines that exemplify its commitment to innovation and excellence. The +PlusCBD brand, a flagship in hemp extract supplements, has earned recognition for its research-backed approach and quality assurance through clinical studies and laboratory testing. Complementing this is the Cultured Foods brand, which provides a variety of 100% plant-based foods designed to meet the nutritional demands of vegan, gluten-free, and flexitarian consumers. The company has also recently expanded into pet wellness with specialized products designed to support joint health and calming effects for companion animals, an innovation that further extends its market reach.

Quality, Research, and Safety

A major component of CV Sciences' value proposition is its dedication to quality and safety. The company was one of the first to invest in generating scientific evidence required to obtain self-affirmed Generally Recognized as Safe (GRAS) status, particularly for its hemp extract supplements. Clinical research data and published studies support product benefits, ensuring that customers receive products that are not only natural but are scientifically validated for efficacy and safety. Independent laboratory tests and adherence to Good Manufacturing Practices (GMP) further solidify the company’s commitment to producing reliable and high-quality nutraceuticals.

Market Position and Competitive Landscape

Operating in the highly competitive consumer wellness and nutraceutical space, CV Sciences has distinguished itself through its diversified product portfolio and a robust focus on scientific research. Its offerings cater to a range of consumer needs, from natural wellness supplements to innovative pet care products, allowing the company to capture multiple market segments. The breadth of its product lines, combined with strategic measures such as mergers and acquisitions, positions CV Sciences as a resilient and adaptive participant in the natural products market. Detailed market insights and trend analyses reinforce its approach, ensuring that the company maintains a competitive edge in a rapidly evolving industry.

Global Presence and Operational Excellence

With primary offices and facilities strategically located in San Diego, California, and Warsaw, Poland, CV Sciences leverages a global operational framework to optimize production and distribution channels. The company’s strategic acquisitions, including Elevated Softgels and Extract Labs, enhance its manufacturing capabilities while providing operational flexibility and cost efficiencies. This global footprint underpins its long-standing commitment to excellence, ensuring consistent quality and timely delivery of state-of-the-art wellness products to customers worldwide.

Strategic Acquisitions and Integration

The proactive pursuit of strategic acquisitions bolsters CV Sciences’ operational capacity and enriches its product innovation pipeline. By integrating companies with complementary technologies and manufacturing strengths, such as Elevated Softgels and Extract Labs, the firm has expanded its ability to produce cost-effective and high-quality encapsulated supplements and tinctures. These acquisitions not only streamline the supply chain but also provide synergistic benefits that translate into enhanced market responsiveness and broader product offerings.

Commitment to Science and Consumer Wellness

At its core, CV Sciences is driven by a mission that combines scientific rigor with natural wellness. Every segment of its operation is designed to uphold the values of transparency, quality, and reliability. Whether through the development of hemp extract-based solutions, the diversification into cannabinoid-free wellness products under the +PlusHLTH brand, or the careful formulation of pet care products, the company consistently demonstrates its dedication to consumer well-being. This scientifically-oriented approach, coupled with a commitment to continuous innovation, underscores the company’s role as an authoritative source in the wellness industry.

In summary, CV Sciences offers a well-rounded, research-informed perspective on modern health and nutrition by providing a diverse array of nutraceutical and plant-based foods. Its strategic emphasis on scientific validation and operational excellence makes it a noteworthy name for anyone seeking comprehensive and quality-driven wellness solutions.

Rhea-AI Summary

CV Sciences (OTCQB: CVSI) announced its first quarter 2024 financial results.

The company generated $4.0 million in revenue, a 2.6% rise from the previous quarter but a 4% year-over-year decline. Its gross margin improved to 46.3% compared to 43.0% in Q1 2023 and 45.8% in Q4 2023. However, the cash balance dropped to $0.7 million from $1.3 million at the end of 2023. The company reported a $0.6 million operating loss, partly due to decreased B2B sales, although B2C sales rose by 3%. The acquisition of Elevated Softgels was highlighted as a strategic move for future growth. CV Sciences remains the top-selling hemp extract brand in natural product retail channels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

CV Sciences (OTCQB:CVSI) has acquired Elevated Softgels, a GMP-certified and FDA-registered manufacturer of encapsulated softgels and tinctures. Elevated Softgels' flexible production capabilities allow CV Sciences to in-source production of key products, potentially leading to significant cost savings. The acquisition involves a total consideration of up to $1,000,000, including a cash payment of $100,000, shares valued at $700,000, and up to $200,000 in performance-based earn-outs. Elevated Softgels, now a wholly-owned subsidiary, is expected to contribute to immediate growth and long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

CV Sciences, Inc. will announce its first-quarter 2024 financial results on May 14, 2024. The company specializes in hemp extracts and natural products. The conference call with the investment community will take place at 7:00 a.m. Pacific Time on the same day. Interested investors can access the webcast on the Investor Relations section of the company's website, and a telephone replay will be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
CV Sciences, Inc. reported financial results for fiscal 2023, showing a revenue of $16.0 million with a gross margin of 44.3%. Despite a slight decrease in sales, the company saw improvements in operating income and adjusted EBITDA. CV Sciences continued to expand its product offerings, launch new CBD products, receive patent approvals, and acquire Cultured FoodsTM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. launches +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews, backed by a safety study from the National Animal Supplement Council. The chews aim to improve pets' physical and emotional well-being with CBD and other natural ingredients, addressing joint pain and anxiety. The products are available nationwide and uphold strict quality standards, offering pet owners a safe and effective alternative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CV Sciences, Inc. (CVSI) will release financial results for the year and fourth quarter ended December 31, 2023, on March 28, 2024. The Company will hold a conference call with investors on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25%
Tags
Rhea-AI Summary
CV Sciences, Inc. (OTCQB: CVSI) has completed the acquisition of Cultured Foods, a leading manufacturer and distributor of alternative plant-based vegan foods, for a total consideration of up to $535,000. The acquisition creates opportunities for importation of specialty foods to the US and establishes a European base of operations for the sale and distribution of +PlusCBD products, contributing to the transition of CV Sciences into a more diverse global health and wellness company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. (OTCQB:CVSI) announced its financial results for the quarter ended September 30, 2023, with increased revenue to $4.1 million, recognized gross margin of 45.1%, and a cash balance of $1.6 million. The company also launched new products, executed an M&A strategy, and evaluated partnership opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
CV Sciences, Inc. (OTCQB:CVSI) will release financial results for the third quarter ended September 30, 2023, before the stock market opens on Tuesday, November 14, 2023. The company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. Investors interested in participating in the live call can also dial (877) 300-8521 from the U.S. or international callers can dial (412) 317-6026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
CV Sciences launches +PlusCBD™ Reserve Collection Sleep Gummies to expand into the sleep aid market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Cv Sciences (CVSI)?

The current stock price of Cv Sciences (CVSI) is $0.0306 as of April 1, 2025.

What is the market cap of Cv Sciences (CVSI)?

The market cap of Cv Sciences (CVSI) is approximately 5.7M.

What core business does CV Sciences focus on?

CV Sciences specializes in consumer wellness products by integrating science and natural ingredients. Its operations include the development and distribution of hemp extract supplements, plant-based foods, and pet wellness products.

How does CV Sciences ensure product quality and safety?

The company adheres to stringent quality standards including GMP-certification and independent laboratory testing. Its products are supported by clinical research and published studies, ensuring safety and efficacy.

What distinguishes the +PlusCBD brand?

The +PlusCBD brand is known for its science-backed approach, clinical research support, and self-affirmed GRAS status. It is recognized as a top-selling hemp extract supplement within the natural products market.

What role do strategic acquisitions play in CV Sciences' growth?

Strategic acquisitions like Elevated Softgels and Extract Labs enhance the company’s manufacturing capabilities and operational flexibility. These moves allow CV Sciences to in-source production and expand its product portfolio cost-effectively.

How does CV Sciences cater to the pet wellness market?

CV Sciences has developed specialized pet products, such as CBD-infused chews for joint and calming health, which are supported by rigorous research and validated by safety studies. These offerings extend the company’s commitment to consumer well-being to pet care.

What is CV Sciences' approach to innovation?

Innovation at CV Sciences is driven by a commitment to scientific research and the integration of natural ingredients. The company continuously develops new products and explores strategic opportunities to enhance its portfolio and market reach.

Which sales channels does CV Sciences use to reach its customers?

CV Sciences employs a diverse sales strategy that includes both B2B and B2C channels. This allows the company to effectively distribute its wellness products through selected retail locations as well as direct consumer platforms.

How does the company maintain its global operational efficiency?

With key facilities in San Diego and Warsaw, CV Sciences leverages a global operational framework. Strategic acquisitions and a focus on manufacturing excellence ensure that the company maintains high standards in production and distribution.
Cv Sciences

OTC:CVSI

CVSI Rankings

CVSI Stock Data

5.71M
184.23M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego